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Abstract
Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and
Food Allergens (NDA) was asked to deliver an opinion on 2’-fucosyllactose/difucosyllactose (2’-FL/DFL)
mixture as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The NF is a powdered mixture
mainly composed of two oligosaccharides, 2’-FL and DFL, which are produced together by
fermentation with a genetically modified strain of Escherichia coli K12. The information provided on the
manufacturing process, composition and specifications of the NF does not raise safety concerns. The
applicant intends to add the NF in a variety of foods, including infant and follow-on formula, foods for
infants and young children, foods for special medical purposes and food supplements. The target
population is the general population except for food supplements, for which the target population is
individuals above 1 year of age. Since the intake of 2’-FL and DFL from the NF at the proposed use
levels is unlikely to exceed the intake level of naturally occurring 2’-FL and DFL in breastfed infants per
kilogram body weight, the Panel concludes that the NF, a mixture of 2’-FL and DFL, is safe under the
proposed conditions of use for the proposed target population.
© 2019 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf
of European Food Safety Authority.
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Summary
Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition
and Allergies (NDA) was asked to deliver a scientific opinion on 2’-fucosyllactose/difucosyllactose
(2’-FL/DFL) mixture as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The assessment of
the safety of this NF, which follows the methodology set out in the EFSA Guidance on the preparation
and presentation of an application for authorisation of a novel food in the context of Regulation (EU)
2015/2283 and in the Commission Implementing Regulation (EU) 2017/2469, is based on the data
supplied in the application, information submitted by the applicant following the European Food Safety
Authority (EFSA) requests for supplementary information and additional data identified by the Panel.
The NF is a mixture mainly composed of two oligosaccharides, 2’-FL and DFL, which are obtained
by fermentation with a genetically modified strain of Escherichia coli K12. The information provided on
the manufacturing process, composition and specifications of the NF does not raise safety concerns.
The applicant intends to add the NF in a variety of foods, including infant and follow-on formula (IF
and FOF), foods for infants and young children, foods for special medical purposes and food
supplements. The target population is the general population except for food supplements, for which
the target population is individuals above 1 year of age.
Considering that 2’-FL and DFL are naturally occurring oligosaccharides present in human milk, the
history of human exposure to 2’-FL and DFL concerns breast-fed infants. The Panel notes that 2’-FL,
which is the major component of the NF, has already been assessed and authorised as a NF to be
added to IF, FOF, to a variety of foods as well as to food supplements.
The Panel considers that there are no concerns regarding genotoxicity of the NF.
The Panels considers that a no observed adverse effect level could not be established from the
90-day oral toxicity study with the NF. However, the intake of 2’-FL and DFL in breastfed infants on a
per kg body weight (bw) basis is expected to be safe also for other population groups.
The anticipated daily intake of the NF from the consumption of IF (only), in infants up to 16 weeks
of age, does not exceed the high intake level of 2’-FL and DFL in breastfed infants per kg bw. The
anticipated daily intake of the NF for the proposed uses at their respective maximum use levels is
unlikely to exceed the high intake level of 2’-FL and DFL in breastfed infants per kg bw. The maximum
daily intake of the NF as food supplements (i.e. 4 g/day) for individuals above 1 year of age does not
exceed the high intake level of 2’-FL and DFL in breastfed infants per kg bw. Thus, the Panel considers
that the intake of the NF for the proposed uses at their respective maximum use levels can be
considered safe.
The Panel concludes that the NF, a mixture of 2’-FL and DFL, is safe under the proposed conditions
of use. The target population is the general population, except for food supplements for which the
target population is individuals above 1 year of age. Food supplements are not intended to be used if
other foods with added NF or 2’-FL (as well as breast milk for young children) are consumed the same
day.
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1. Introduction
1.1. Background and Terms of Reference as provided by the European
Commission
On 30 April 2018, the company Glycom A/S submitted a request to the European Commission in
accordance with Article 10 of Regulation (EU) No 2015/22831 to place on the EU market 2’-
fucosyllactose/difucosyllactose mixture as a novel food (NF). The 2’-fucosyllactose/difucosyllactose
mixture is intended to be used in a number of food categories.
In accordance with Article 10(3) of Regulation (EU) 2015/2283, the European Commission asks the
European Food Safety Authority to provide a scientific opinion on 2’-fucosyllactose/difucosyllactose
mixture as a NF.
2. Data and methodologies
2.1. Data
The safety assessment of this NF is based on data supplied in the application and information
submitted by the applicant following EFSA requests for supplementary information.
During the assessment, the Panel identified additional data which were not included in the
application (Urashima et al., 2013, 2018; Oftedal et al., 2014).
Administrative and scientific requirements for NF applications referred to in Article 10 of Regulation
(EU) 2015/2283 are listed in the Commission Implementing Regulation (EU) 2017/24692.
A common and structured format on the presentation of NF applications is described in the EFSA
guidance on the preparation and presentation of a NF application.3 As indicated in this guidance, it is
the duty of the applicant to provide all available (proprietary, confidential and published) scientific
data, including both data in favour and not in favour to supporting the safety of the proposed NF.
This NF application includes a request for protection of proprietary data in accordance with Article
26 of Regulation (EU) 2015/2283. Data claimed to be proprietary by the applicant include:
• annexes to the dossier which relate to the identity, the production process, production
microorganism, composition and specifications of the NF (Annex I ‘NMR Analytical Reports on
Structure Comparison of 2’-FL and DFL from microbial fermentation to breast milk 2’-FL and
DFL’; Annex II ‘Production Strain Data’; Annex III ‘Production Strain Certificates’; Annex IV
‘Raw Materials and Processing Aids’; Annex V ‘Certificates of Analysis and Batch Data’; Annex
VI ‘Analytical Methods and Validation Reports’; Annex VII ‘Stability Reports’; Annex VIII
‘Laboratory Accreditation Certificates’;
• ‘Intake assessment report’ (Annex X to the dossier);
• bacterial reverse mutation test (Unpublished study report, 2017a), in vitro micronucleus test
(Unpublished study report, 2017b), 14-day and 90-day oral toxicity studies with the NF
(unpublished study report, 2017c, 2018, respectively) including the summary table of the
statistically significant observations in the 90-day study (Appendix B.3 to the dossier);
• bacterial reverse mutation test (unpublished study report, 2015c), in vitro micronucleus tests
(unpublished study reports, 2015a,b), and 90-day oral toxicity study with 2’-fucosyllactose
(unpublished study report, 2015d).
1 Regulation (EU) 2015/2283 of the European Parliament and of the Council on novel foods, amending Regulation (EU) No 1169/
2011 of the European Parliament and of the Council and repealing Regulation (EC) No 258/97 of the European Parliament and
of the Council and Commission Regulation (EC) No 1852/2001 (2013/0435 (COD). OJ L 327, 11.12.2015, p. 1–22.
2 Commission Implementing Regulation (EU) 2017/2469 of 20 December 2017 laying down administrative and scientific
requirements for applications referred to in Article 10 of Regulation (EU) 2015/2283 of the European Parliament and of the
Council on novel foods. OJ L 351, 30.12.2017, pp. 64–71.
3 EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), Turck D, Bresson J-L, Burlingame B, Dean T,
Fairweather-Tait S, Heinonen M, Hirsch-Ernst KI, Mangelsdorf I, McArdle H, Naska A, Neuh€auser-Berthold M, Nowicka G,
Pentieva K, Sanz Y, Siani A, Sj€odin A, Stern M, Tome D, Vinceti M, Willatts P, Engel K-H, Marchelli R, P€oting A, Poulsen M,
Salminen S, Schlatter J, Arcella D, Gelbmann W, de Sesmaisons-Lecarre A, Verhagen H and van Loveren H, 2016. Guidance on
the preparation and presentation of an application for authorisation of a novel food in the context of Regulation (EU) 2015/
2283. EFSA Journal 2016;14(11):4594, 24 pp. https://doi.org/10.2903/j.efsa.2016.4594
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2.2. Methodologies
The assessment follows the methodology set out in the EFSA guidance on NF applications and the
principles described in the relevant existing guidance documents from the EFSA Scientific Committee.
The legal provisions for the assessment are laid down in Article 11 of Regulation (EU) 2015/2283 and
in Article 7 of the Commission Implementing Regulation (EU) 2017/2469.
This assessment concerns only risks that might be associated with consumption of the NF under the
proposed conditions of use and is not an assessment of the efficacy of 2’-fucosyllactose/difucosyllactose
mixture with regard to any claimed benefit.
3. Assessment
3.1. Introduction
The NF is a mixture of 2’-fucosyllactose (2’-FL) and difucosyllactose (DFL) obtained by microbial
fermentation using D-lactose and D-glucose as raw materials. The NF is intended to be used in foods
for infants and young children, foods for special medical purposes, total diet replacements for weight
control, food supplements and various foods. The target population is the general population (except
for food supplements which is individuals above 1 year of age). The applicant indicated that this NF
falls under the following categories:
i) ‘food with a new or intentionally modified molecular structure, where that structure was not
used as, or in, a food within the Union before 15 May 1997’; and
ii) ‘food consisting of, isolated from or produced from microorganisms, fungi or algae.’
3.2. Identity of the NF
The NF is a powdered mixture mainly composed of two oligosaccharides, 2’-FL and DFL, which are
produced together by fermentation with a genetically modified strain of Escherichia coli K12. 2’-FL is a
trisaccharide consisting of D-lactose and L-fucose, linked at the D-galactose moiety by an a(1?2) bond
(chemical formula: C18H32O15; molecular mass: 488.44 Da; CAS No 41263-94-9). DFL is a
tetrasaccharide, where a second L-fucose moiety has been added to the 3-position of D-glucose in 2’-FL
by an a(1?3) bond (chemical formula: C24H42O19; molecular mass: 634.58 Da; CAS No 20768-11-0).
The relative structures have been confirmed by monodimensional (1D) and two-dimensional (2D
NOESY) 1H-nuclear magnetic resonance spectroscopy (NMR) and by mass spectrometry (MS). The
structures are consistent with what is reported in the literature (Oftedal et al., 2014; Urashima et al.,
2018). The 2’-FL and DFL obtained by microbial fermentation are demonstrated to be chemically and
structurally identical to the oligosaccharides present in human milk (Pratico et al., 2014).
3.3. Production process
The NF is produced according to Good Manufacturing Practice (GMP) and Hazard Analysis Critical
Control Points (HACCP) principles.
The manufacturing process can be broadly divided into two stages. In the first stage, D-lactose and
D-glucose are converted to 2’-FL and DFL by the modified cellular metabolism of the production
microorganism, which uses D-glucose as an exclusive energy and carbon source and D-lactose as a
substrate for the biosynthesis of 2’-FL and DFL. The production microorganism, which is a genetically
modified derivative of E. coli K-12, is entirely removed from the medium at the end of the fermentation
process (ultrafiltration/diafiltration). The second stage of the process consists of a series of purification,
concentration and isolation steps to obtain the NF as a spray-dried powdered mixture.
The production strain used in the fermentation is a genetically modified derivative of E. coli K-12
DH1. The parental strain E. coli K-12 DH1 (ʎ-gyrA96 recA1 relA1 endA1 thi-1 hsdR17 supE44) was
obtained from the German Collection of Microorganisms and Cell Cultures (DSMZ) and deposited under
DSM No. 4235. Although the species E. coli was considered not suitable for qualified presumption of
safety (QPS) status (EFSA BIOHAZ Panel, 2018), E. coli K-12 is considered as an example of safe and
non-pathogenic or toxigenic microorganism widely used for biotechnological applications (Gorbach,
1978; OECD, 1986; Muhldorfer and Hacker, 1994; U.S. EPA, 1997). The whole genomes of E. coli K-12
and of other derivative strains, including E. coli K12 DH1, were sequenced and compared with other
E. coli strains. The results indicate that E. coli K-12 and its derivatives show genomic differences
compared to pathogenic strains (Blattner et al., 1997; Lukjancenko et al., 2010).
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The genetically modified derivative of the E. coli K-12 DH1 strain, which is used in the production
process of the NF, has been deposited in the DSMZ in Braunschweig, Germany, under DSM No. 32774.
The applicant provided a detailed description of the genetic modification process applied to the
parental strain to obtain the platform strain E. coli K-12 DH1 MDO (membrane-derived oligosaccharide)
and to the final production microorganism.
The absence of the production microorganism in the NF was demonstrated by testing five batches
of the NF for bacteria from the Enterobacteriaceae family according to internationally recognised
methods (ISO 21528-1:2004, MSZ ISO 21528-2:2007). Upon EFSA’s request for additional information,
the applicant provided data to demonstrate the absence of DNA from the genetically modified
production microorganism in the NF in accordance to the EFSA guidance on microorganisms used as
production organisms (EFSA FEEDAP Panel, 2018).
The Panel considers that the production process is sufficiently described and does not raise safety
concerns.
3.4. Compositional data
The applicant provided batch-to-batch composition for five batches of the NF (Table 1), analysed
using high-performance anion exchange chromatography coupled to pulsed amperometric detection
(HPAEC-PAD).
The NF is a mixture mainly composed of two oligosaccharides, 2’-FL and DFL (81% and 11%,
respectively, as the average from five batches of the NF), accompanied by other carbohydrates (e.g.
D-lactose, L-fucose, 2’-L-fucosyl-D-lactulose). Together with other related saccharides naturally occurring
in milk (i.e. lactose, fucose), the 2’-FL/DFL mixture comprises 94% of the total weight (mean from five
batches of the NF). The remaining portion of the product consists mainly of other carbohydrate-type
compounds structurally related to 2’-FL and DFL. Non-carbohydrate residues including amino acids,
amino acid metabolites, biogenic amines, microbial endotoxins, residual proteins, anions, trace
elements and heavy metals were analysed and not detected in the purified product.
The microbiological purity of batches of the NF has been assessed with regard to non-pathogenic
microorganisms (bacteria, yeasts and moulds) as general hygiene indicators, and selected food-borne
pathogens.
The Panel considers that the information provided on the composition of the NF is sufficient and
does not raise safety concerns.






















Appearance Powder or agglomerates
Colour White to off white
pH (20°C, 5% solution) 4.5 4.4 4.6 4.1 4.8 4.5  0.3
Composition
Sum of 2’-FL, DFL, lactose, and
fucose [w/w % dry matter]
93.6 93.2 93.9 94.0 94.4 94  0.4
Sum of 2’-FL and DFL [w/w %
dry matter]
90.6 92.1 92.6 90.3 93.7 92  1
2’-FL [w/w % dry matter] 79.1 82.5 81.7 78.8 81.7 81  2
DFL [w/w % dry matter] 11.5 9.6 10.9 11.5 12.0 11  1
Ratio 2’-FL:DFL 6.9 8.6 7.5 6.9 6.8 7  1
D-Lactose [w/w %] 2.98 0.96 1.29 3.56 0.64 1.9  1.3
L-Fucose [w/w %] 0.05 0.06 0.04 0.09 0.06 0.1  0.0
2’-Fucosyl-D-lactulose [w/w %] 1.1 0.9 0.8 0.8 0.9 0.9  0.1
Sum of other carbohydrates(1)
[w/w %]
2.9 2.4 2.1 2.0 2.2 2.3  0.1
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3.4.1. Stability
Stability of NF
The stability of the NF has been investigated in two representative batches in an ongoing 5-year
study under real-time conditions (25°C, 60% relative humidity (RH)) and in an ongoing 2-year study
under accelerated conditions (40°C, 75% RH). Upon EFSA’s request for additional information, the
applicant provided 12-month interim results of two batches of the NF from these studies. Results on
composition, physical and microbiological parameters have been provided. The results indicate that the
NF is stable when stored at room temperature for at least 12 months.
Stressed/forced stability tests with the NF as amorphous powder and in aqueous solutions, at acidic
or neutral pH, and stored at 60 and 80°C for 8 and 4 weeks, respectively, have been performed. The
results of these studies indicated the presence of two potential pH-dependent chemical pathways in
the aqueous solutions of the NF, i.e. hydrolysis at pH < 5.0 and isomerisation at pH > 6.0. At neutral
pH, 2’-FL and DFL underwent minor isomerisation to fucosyl-lactulose and difucosyl-lactulose,
respectively.
The applicant also referred to stability studies on 2’-FL alone. A 2-year accelerated stability study
(40°C, 75% RH) on the chemically synthesized 2’-FL (crystalline form) demonstrated that 2’-FL is
stable for 3 years, when stored at room temperature (EFSA NDA Panel, 2015).
The applicant provided a 5-year real time stability study on one batch of 2’-FL (amorphous
powder), at room temperature, which confirms the 5 years shelf-life of the amorphous 2’-FL upon
storage at 25°C.
The Panel considered that the available data provide sufficient information with respect to the
stability of the NF.
Stability of NF under the intended conditions of use
The stability of the NF in powdered infant formula has been investigated when stored at 4, 20, 30
and 37°C up to 6 months.
The infant formula powder tested was a whey-based commercially available formula supplemented






















Water [w/w %] 0.38 0.44 0.42 0.44 0.47 0.43  0.03
Ash, sulfated [w/w %] 0.02 0.06 0.03 0.01 0.07 0.04  0.03
Microbiological parameters
Aerobic mesophilic total plate
count [CFU/g]
< 10 < 10 < 10 < 10 < 10 < 10
Enterobacteriaceae [in 10 g] Absent Absent Absent Absent Absent Absent
Salmonella spp. [in 25 g] Absent Absent Absent Absent Absent Absent
Cronobacter (Enterobacter)
sakazakii [in 10 g]
Absent Absent Absent Absent Absent Absent
Listeria monocytogenes [in 25 g] Absent Absent Absent Absent Absent Absent
Bacillus cereus [CFU/g] < 10 < 10 < 10 < 10 < 10 < 10
Yeasts [CFU/g] < 10 < 10 < 10 < 10 < 10 < 10
Moulds [CFU/g] < 10 < 10 < 10 < 10 < 10 < 10
2’-FL: 2’-fucosyllactose; CFU: colony forming units; DFL: difucosyllactose.
(1): Sum of carbohydrates such as 3’-fucosyllactose (3’-FL), 2’-fucosyl-galactose, glucose, galactose, mannitol, sorbitol,
galactitol, trihexose, allo-lactose and other structurally related carbohydrates.
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3.5. Specifications
The specifications of the NF as proposed by the applicant are presented in Table 2. The parameters
include the main components of the mixture (2’-FL and DFL), the raw material D-lactose and possible
degradation products (L-fucose and 2’-L-fucosyl-D-lactulose).
Microbiological parameters for Listeria monocytogenes, Cronobacter (Enterobacter) sakazakii and
Bacillus cereus are monitored through internal specifications.
Analyses were performed using internationally recognised methods or newly developed and
validated analytical protocols at Glycom’s Research & Development Department and confirmed by
accredited laboratories.
The Panel considers that the information provided on the specifications of the NF is sufficient and
does not raise safety concerns.
Table 2: Specifications of the NF
Description: The 2ʹ-fucosyllactose/difucosyllactose (2’-FL/DFL) mixture is a purified, white to off-white
amorphous powder that is produced by a microbial process. After purification, the 2ʹ-FL/DFL powdered mixture is
obtained by spray drying
Source: A genetically modified strain of Escherichia coli K-12 DH1 DMO
Parameter Specification Method
Appearance Powder or agglomerates ISO 6658:2007
Colour White to off white ISO 6658:2007
Identification (2’-FL/DFL mixture) RT of standards  3% HPAEC/PAD
Sum of 2’-FL, DFL, lactose and fucose
[% dry matter]
≥ 92.0 w/w % HPAEC/PAD
Sum of 2’-FL and DFL [% dry matter] ≥ 85.0 w/w % HPAEC/PAD
2’-FL [% dry matter] ≥ 75.0 w/w % HPAEC/PAD
DFL [% dry matter] ≥ 5.0 w/w % HPAEC/PAD
D-Lactose ≤ 10.0 w/w % HPAEC/PAD
L-Fucose ≤ 1.0 w/w % HPAEC/PAD
2’-Fucosyl-D-lactulose ≤ 2.0 w/w % HPAEC/PAD
Sum of other carbohydrates(1) ≤ 6.0 w/w % HPAEC/PAD
pH (20°C, 5% solution) 4.0–6.0 Eur. Ph. 9.2 2.2.3 (07/2016:20203)
Water ≤ 6.0 w/w % Karl-Fischer
Ash, sulfated ≤ 0.8 w/w % Eur. Ph. 9.2 2.4.14 (04/2010:20414)
Residual protein ≤ 0.01 w/w % Bradford assay (UV spectroscopy)(2)
Microbiological Parameters
Aerobic mesophilic total plate count ≤ 1000 CFU/g ISO 4833-1:2014
Enterobacteriaceae ≤ 10 CFU/g ISO 21528-1:2004, ISO 21528-2:2007
Salmonella spp. Absent in 25 g ISO 6579:2006
Yeasts ≤ 100 CFU/g ISO 7954:1999
Moulds ≤ 100 CFU/g ISO 7954:1999
Residual endotoxins ≤ 10 EU/mg Eur. Ph. 2.6.14
2’-FL: 2’-fucosyllactose; CFU: colony forming units; DFL: difucosyllactose; EU: endotoxin units; Eur. Ph.: European
Pharmacopoeia; HPAEC/PAD: high-performance anion exchange chromatography/pulsed amperometric detection; RT: retention
time; UV: ultraviolet.
(1): Sum of carbohydrates such as 3’-fucosyllactose (3’-FL), 2’-fucosyl-galactose, glucose, galactose, mannitol, sorbitol,
galactitol, trihexose, allo-lactose and other structurally related carbohydrates.
(2): LOR = 17 mg/kg.
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3.6. History of use of the NF
3.6.1. History of use of the NF
The NF as such does not have a history of use.
However, 2’-FL, which is the major constituent of this NF, has been authorised as a NF in the
European Union (Commission Implementing Regulation 2018/10234) to be added to infant and follow-
on formulae (IF, FOF), to a variety of foods as well as to food supplements. 2’-FL is obtained either
from fermentation with genetically modified E. coli strains (K12 or BL21) or by chemical synthesis. The
production of these already authorised 2’-FL results in the presence of DFL (up to 5%) in the final
product.
2’-FL has also been authorised to be used as a food ingredient in USA and Singapore (FDA, 2015,
2016; AVA, 2018).
3.6.2. Consumption of 2’-FL and DFL in breast milk
Human breast milk contains a family of structurally related oligosaccharides, known as human milk
oligosaccharides (HMOs), which constitute the third main component in human milk after lactose and
fats. 2’-FL and DFL belong to the group of fucosylated HMOs, which constitute on average around
70% of the total HMO fraction in human milk (Bode, 2012).
Several publications on 2’-FL and DFL in human milk have been provided by the applicant. The
amount of 2’-FL and DFL in human milk depends on the lactation period, with higher levels reported in
colostrum (Coppa et al., 1999, 2011; Erney et al., 2000; Morrow et al., 2004; Musumeci et al., 2006;
Asakuma et al., 2008, 2011; Thurl et al., 2010, 2017; Galeotti et al., 2012, 2014; Spevacek et al.,
2015; Austin et al., 2016; McGuire et al., 2017). Erney et al. (2001) reported mean concentrations of
2.38 g/L for 2’-FL and 0.46 g/L for DFL, in pooled human milk samples from different lactating
periods, with high occurrence levels of 4.78 g/L for 2’-FL and 2.44 g/L for DFL reported in individual
samples.
Based on the mean and high occurrence levels of 2’-FL and DFL in human milk as reported by
Erney et al. (2001), and considering the average and high daily intake of breast milk (800 mL and
1,200 mL, respectively) for infants from 0 to 6 months (EFSA NDA Panel, 2013), the NDA
Panel calculated the daily intake levels of 2’-FL and DFL per kg body weight (bw) from human milk for
an infant with a default bw of 6.75 kg (Table 3). The default bw used by the NDA Panel is for an
infant of 3–6 months of age, who is more likely to consume such amounts of human milk.
Oligosaccharides, including 2’-FL and DFL, have also been detected in domestic farm animal milk,
however, at lower concentrations as compared to human milk (Aldredge et al., 2013; Urashima et al.,
2013; Albrecht et al., 2014).
Table 3: Estimated daily intake levels of 2’FL and DFL from human milk (800 mL and 1,200 mL) for
infants of 6.7 kg bw, based on mean and high concentration of 2.38 g/L and 4.78 g/L,
respectively, of 2’-FL and mean and high concentration of 0.46 g/L and 2.44 g/L,
respectively, of DFL in human milk
Daily intake levels (mg/kg bw)
from 800 mL of human milk
Daily intake levels (mg/kg bw)
from 1,200 mL of human milk
Mean concentration High concentration Mean concentration High concentration
2’FL 284 571 426 856
DFL 55 291 82 437
2’-FL: 2’-fucosyllactose; DFL: difucosyllactose bw: body weight.
4 Commission Implementing Regulation (EU) 2018/1023 of 23 July 2018 correcting Implementing Regulation (EU) 2017/2470
establishing the Union list of novel foods. Official Journal of the European Union L 187, 1–133.
5 EFSA Scientific Committee, 2012.
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3.7. Proposed uses and use levels and anticipated intake
3.7.1. Target population
The target population proposed by the applicant is the general population, except for food
supplements for which the target population is individuals above 1 year of age.
3.7.2. Proposed uses and use levels
The NF is intended to be added to a variety of foods, at the maximum use levels as indicated in
Table 4. The Panel notes that for ‘Foods for special medical purposes’ the applicant did not propose
either maximum use levels or maximum intake levels.
The applicant also intends to market the NF as food supplements, at the maximum daily intake of
4 g, for individuals above 1 year of age.




Food category name Proposed maximum use level of the NF
1 Dairy products and analogues
1.1 Unflavoured pasteurised and unflavoured
sterilised (including UHT) milk
2.0 g/L
1.2/1.3 Unflavoured fermented milk-based products 2.0 g/L beverages
20 g/kg products other than beverages
1.4 Flavoured fermented milk-based products
including heat-treated products
2.0 g/L beverages
20 g/kg products other than beverages
7 Bakery wares
7.2 Fine bakery wares. Cereal bars only 20 g/kg
13 Foods for Special Groups
13.1 Foods for infants and young children
13.1.1 Infant formula as defined in Regulation (EU)
No 609/2013
1.6 g/L in the final product ready for use, marketed
as such or reconstituted as instructed by the
manufacturer
13.1.2 Follow-on formula as defined in Regulation
(EU) No 609/2013
1.2 g/L in the final product ready for use, marketed
as such or reconstituted as instructed by the
manufacturer
13.1.3 Processed cereal-based food and baby food
for infants and young children as defined in
Regulation (EU) No 609/2013
1.2 g/L in the final product ready for use, marketed
as such or reconstituted as instructed by the
manufacturer
10 g/kg for products other than beverages
13.1.413 Milk-based drinks and similar products
intended for young children
1.2 g/L in the final product ready for use, marketed
as such or reconstituted as instructed by the
manufacturer
10 g/kg for products other than beverages
13.2 Foods for special medical purposes as defined in Regulation (EU) No 609/2013
13.2 Foods for special medical purposes as
defined in Regulation (EU) No 609/2013
On case-by-case basis
13.3 Total diet replacement for weight control as defined in Regulation (EU) No 609/2013
13.3 Total diet replacement for weight control as
defined in Regulation (EU) No 609/2013
4.0 g/L beverages
40 g/kg products other than beverages
14 Beverages
14.1.4 Flavoured drinks 2.0 g/L
UHT: ultra-high temperature.
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3.7.3. Anticipated intake of the NF
Anticipated intake of the NF from the consumption of IF in infants up to 16 weeks of age
IF is expected to be the only food consumed by infants aged 0–16 weeks. The high consumption of
IF has been estimated to be 260 mL/kg bw per day for infants aged 0–16 weeks (EFSA Scientific
Committee, 2017). Based on the maximum proposed use level of the NF (1.6 g/L in IF), the high
intake of the NF from IF alone is estimated to be 416 mg/kg bw per day.
Considering the mean content of 81% and 11% for 2’-FL and DFL, respectively, in the NF (as
indicated in Table 1), the daily intake of 2’-FL and DFL from the consumption of IF added with the NF
corresponds to 337 mg/kg bw for 2’-FL and 46 mg/kg bw for DFL, respectively. The Panel notes that
the anticipated daily intake of the NF from the consumption of IF (only) does not exceed the
estimated high daily intake of 2’-FL and DFL in breast-fed infants per kg bw (Table 3). The Panel notes
that the proposed maximum use level of 2’-FL from the NF in IF (i.e. 1.6 g/L) is in line with the
maximum use level already authorised for 2’-FL in IF.4
Anticipated intake of the NF from the proposed food uses
The applicant estimated the daily intake of the NF by using the EFSA Food Additive Intake model
(FAIM) tool (FAIM 2.0, 2017). However, since the food categories in the FAIM tool, which are based on
Regulation (EC) 1333/2008, do not allow a precise matching with the food categories proposed for the
NF, the intake estimations performed by the applicant resulted in high and uncertain estimated intakes.
Thus, EFSA performed a refined estimate of the anticipated daily intake of the NF, at the maximum
proposed use levels of the NF, using individual data from the EFSA Comprehensive Food Consumption
Database (EFSA, 2011) and by applying the FoodEx2 classification system (Table 5). The lowest and
highest mean and 95th percentile anticipated daily intake of the NF for all subjects, among the EU
dietary surveys, are presented in Table 6. The refined anticipated daily intake of the NF for each
population group from each EU dietary survey is available in the excel file annexed to this scientific
opinion (under supporting information).
Anticipated intake of 2’-FL from the proposed uses and use levels of the NF
The Panel notes that all proposed uses of the NF have already been authorised for a NF which
consists of 2’-FL.4 Considering 81% 2’-FL content in the NF, the maximum proposed use levels of 2’-FL
from the NF under assessment are in line with the maximum use levels authorised for 2’-FL.4
The Panel also notes that the highest estimated 95th percentile intake of 2’-FL from the NF (i.e.
1,110 mg kg bw = 81% of 1,370 mg NF per kg bw) on the basis of 11 dietary surveys covered by the
EFSA Comprehensive Food Consumption Database is about 30 % above the high estimate for 2’-FL
from human milk (i.e. 856 mg/kg bw). Considering that the exposure of 2’-FL from human milk is only
exceeded in one out of the 11 dietary surveys included in the EFSA Comprehensive Food Consumption
Database and the conservative assumption underlying this type of exposure assessment, in particular,
assuming that all foods of the proposed food categories consumed by infants are added with the NF at
the maximum proposed use levels, the Panel considers that it unlikely that infants would exceed high
intake levels of 2’-FL from human milk per kg bw.
Anticipated intake of DFL from the proposed uses and use levels of the NF
Based on 11% DFL content in the NF, the anticipated daily intake of DFL is calculated from the
highest 95th percentile anticipated daily intake of the NF (Table 7). The Panel notes that the highest
anticipated 95th percentile daily intake of DFL from the NF when added to all food categories listed in
Table 5, at the maximum proposed use levels, does not exceed for any group of the general
population the high daily intake of DFL in breastfed infants per kg bw (Table 3).
Table 5: FoodEx2 categories and maximum use levels of the NF used in the refined intake of the






Maximum use level of
the NF mg/100 g
A02LV 5 Cow milk 200
A0CXA 5 European buffalo milk 200
A02MC 5 Sheep milk 200
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Maximum use level of
the NF mg/100 g
A02MB 4 Goat milk 200
A02MV 3 Butter milk 200
A02NQ 4 Yoghurt drinks 200
A02NR 4 Probiotic milk-like drinks 200
A02NV 5 Kefir 200
A02NE 4 Yoghurt 2,000
A00EY 4 Cereal bars 2,000
A00EZ 4 Cereal bars plain 2,000
A00FA 4 Cereal bars mixed 2,000
A03PZ 4 Infant formulae, powder 1,300
A03QE 4 Infant formulae, liquid 160
A03QK 4 Follow-on formulae, powder 970
A0EQL 4 Follow-on formulae, liquid 120
A03QZ 3 Cereals with an added high protein food which have to be
reconstituted
600
A03QY 3 Simple cereals which have to be reconstituted 600
A0BZF 3 Cereals with added high protein food reconstituted 120
A0BZE 3 Simple cereals for infants and children reconstituted 120
A03RA 3 Biscuits, rusks and cookies for children 1,000
A03RC 2 Ready-to-eat meal for infants and young children 1,000
A03RB 3 Pasta for children 1,000
A03RN 3 Fruit and vegetable juices and nectars specific for infants
and young children
120
A03RP 3 Special food for children’s growth 120
A03RT 4 Total daily diet replacement for weight reduction 4,000
A0EQN 5 Soft drinks with minor amounts of fruits or flavours 200
A03A 5 Soft drink with fruit juice (fruit content below the minimum
for nectars)
200
A03EX 5 Soft-drink, flavoured, no fruit 200
A03FQ 4 Cola type drinks 200
NF: novel food.
Table 6: Ranges among EU surveys of the estimated daily intake of the NF (mg/kg bw), based on
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Anticipated intake of the NF from food supplements
The applicant has proposed a maximum daily intake of 4 g of the NF as food supplements for
individuals above 1 year of age. Food supplements are not intended to be used if other foods with
added NF or 2’-FL are consumed the same day. For young children (aged 12–35 months), food
supplements are not intended to be used if breast milk or other foods with added NF or 2’-FL are
consumed the same day.
Considering the mean content of 81% and 11% for 2’-FL and DFL, respectively, the maximum daily
intake of the NF (i.e. 4 g/day) results in a maximum daily intake of 272 mg/kg bw and 37 mg/kg bw
of 2’-FL and DFL, respectively, for young children with bw of 11.9 kg (default body weight value
indicated by the EFSA Scientific Committee for young children of 12–35 months of age (2012)). For
individuals above 3 years of age, the maximum daily intake of the NF from food supplements in mg
per kg bw would be lower than that for young children. The Panel notes that the maximum proposed
daily intake of the NF as food supplements (i.e. 4 g/day) for individuals above 1 year of age does not
exceed the high daily intake of 2’-FL and DFL from human milk per kg bw for infants (Table 3).
3.7.4. Combined intake from the NF and other sources
As indicated in Section 3.6.1, 2’-FL, which is the major component of the NF under assessment,
has been authorised as a NF. The Panel notes that more uses than those proposed for the NF under
assessment have been authorised for 2’-FL (i.e. dairy analogues; table-top sweeteners; bread and









among EU dietary surveys
Range of 95th percentile
(lowest and highest)




Pregnant women 2 5–24 14–75
Lactating women 2 20-28 74-77
NF: novel food; bw: body weight.
Table 7: Estimated daily intake of DFL (mg/kg bw) from the highest 95th percentile of intake of the





Highest 95th percentile among EU dietary
surveys (as reported in table 6)
For DFL
Highest 95th percentile



















Pregnant women 75 8
Lactating women 77 8
DFL: difucosyllactose; NF: novel food; bw: body weight
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Considering that DFL can be potentially present up to a maximum limit of 5% in the already
authorised 2’-FL, the additional authorised uses for 2’-FL which were listed above constitute an
additional source of intake of DFL. Overall, the contribution to the DFL intake from the additional
already authorised uses of 2’-FL can be considered low (i.e. less than 5% of the highest 95th
percentile intake).
Food supplements are not intended to be used if other foods with added NF or 2’-FL (as well as
breast milk for young children) are consumed the same day.
3.8. Absorption, distribution, metabolism and excretion (ADME)
HMOs, including fucosyllactoses, are considered ‘non-digestible oligosaccharides’ (EFSA NDA Panel,
2014). HMOs, such as 2’-FL and DFL, do not undergo any significant digestion in the upper
gastrointestinal tract (Brand-Miller et al., 1995, 1998; Engfer et al., 2000; Gnoth et al., 2000;
Chaturvedi et al., 2001b; Rudloff and Kunz, 2012).
Brand-Miller et al. (1995, 1998) reported that HMOs, consumed as a load (a purified
oligosaccharide fraction from human milk), are fermented in the colon by intestinal microbiota.
Chaturvedi et al. (2001b) and Coppa et al. (2001) reported that 97% and 40–50% of the ingested
HMOs are excreted unchanged in faeces in breast-fed infants. Approximately 1–2% of the ingested
amounts of HMOs are excreted unchanged in the infants’ urine.
There are no reasons to assume that the absorption of 2’-FL and DFL, which are the main
constituents of the NF, may differ from the absorption of 2’-FL and DFL from human milk.
The Panel considers that limited digestion of the NF occurs in the upper gastrointestinal tract and
that only small amounts are expected to be absorbed.
3.9. Nutritional information
The NF is mainly composed of two non-digestible oligosaccharides, i.e. 2’-FL and DFL. The
Panel considers that consumption of the NF at the proposed use levels is not nutritionally
disadvantageous.
3.10. Toxicological information
The list of toxicological studies, which were provided and claimed proprietary by the applicant, is
provided in Table 8. These studies were conducted with the NF (batch no CPN6317 1000517 FD),
which contained 82.5% of 2’-FL and 9.64% of DFL.
The applicant also provided toxicological studies on 2’-FL (alone), which was chemically synthesized
or produced using different genetically modified strains of E. coli (BL21 or K-12) than the one used to
produce the NF. The Panel considers that these toxicological studies on 2’-FL can provide supporting
evidence for the safety assessment of the NF.
3.10.1. Genotoxicity
The potential genotoxicity of the NF was investigated in a bacterial reverse mutation test and an
in vitro mammalian cell micronucleus test (Unpublished study report, 2017a,b, Phipps et al., 2018).
These studies were conducted in compliance with Organisation for Economic Co-operation and
Development (OECD) principles of Good Laboratory Practice (GLP) (OECD, 1998a) and in accordance
with the test guidelines No 471 and 487 from OECD (1997, 2014).
In the bacterial reverse mutation test, Salmonella Typhimurium TA98, TA100, TA1535 and TA1537
and E. coli strain WP2 uvrA (pKM101) were exposed to the NF at concentrations up to 5,000 lg/plate
Table 8: List of toxicological studies with the NF provided by the applicant
Test material Reference Type of study
NF
(82.5% 2’-FL and 9.64%
DFL)
Unpublished study report (2017a);
Phipps et al. (2018)
Bacterial reverse mutation test (Ames test)
Unpublished study report (2017b);
Phipps et al. (2018)
In vitro mammalian cell micronucleus test
Unpublished study report (2017c) 14-day repeated dose oral toxicity study
Unpublished study report (2018);
Phipps et al. (2018)
90-day repeated dose oral toxicity study
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(either in the absence or presence of S9 mix). No cytotoxicity was observed up to the highest
concentration tested. No biologically relevant increase in the number of revertant colonies was
observed (with or without S9-mix) up to the highest concentrations tested. The NF is non-mutagenic
in this assay.
In the in vitro mammalian cell micronucleus test, human lymphocytes were exposed to the NF at
concentrations up to 2,000 lg/mL (either in the absence or presence of S9 mix) in both a preliminary
and main test. No cytotoxicity was observed up to the highest concentration tested. There was no
statistically significant increase in the number of micronucleated cells (with or without S9-mix). The NF
is neither clastogenic nor aneugenic in this assay.
Based on the results of these studies, the Panel considers that there are no concerns regarding
genotoxicity of the NF.
3.10.2. Repeated dose toxicity studies
The applicant provided a 14-day repeated dose oral toxicity study in Crl:CD(SD) neonatal rats of 7
days of age (8/sex per group) which were administered by gavage 0, 4,000 or 5,000 mg/kg bw per
day of the NF (Unpublished study report, 2017c). No claim for compliance with GLP was made. One
male in the 5,000 mg/kg bw group was found dead at the end of the treatment period. The cause of
the death could not be determined. Transient clinical signs were observed in some animals in both
treated groups (i.e. red and/or yellow staining around the anus) and were considered non-adverse. No
test-item related effects were observed in this study (i.e. body weight and macroscopic abnormalities).
Thus, the authors concluded that the highest dose tested (i.e. 5,000 mg/kg bw per day) would be
acceptable as the high-dose level for a 90-day toxicity study in neonatal rats.
The applicant provided a repeated dose toxicity study in which Crl:CD(SD) neonatal rats of 7 days
of age (10/sex per group) were administered by gavage either 0, 1,000, 3,000 or 5,000 mg/kg bw per
day of the NF, or 5,000 mg/kg bw per day of oligofructose for 90 days (Phipps et al., 2018;
Unpublished study report, 2018). Additional groups (5/sex per group) administered by gavage 0 or
5,000 mg/kg bw per day of the NF, or 5,000 mg/kg bw per day of oligofructose for 90 days were
followed for a 4-week treatment-free recovery period. This study was conducted in compliance with
OECD principles of GLP (OECD, 1998a) and in accordance to the principles and methods described in
the test guideline No 408 from OECD (1998b) and in the EMA guideline on repeated dose toxicity
(EMA, 2010), with the exception of the age of rats.
Statistically significant differences in some parameters, between the treated and the control groups,
have been observed (see Appendix A to this opinion).
Mean activity count in high-dosed females was statistically significantly lower than controls. As this
effect was slight and only observed in females, and owing to a no dose–response relationship, this
effect it is considered unrelated to the test material.
Mean age and body weight at balano-preputial skinfold separation were slightly higher in high-
dosed males as compared with controls (only age was statistically significantly higher and not body
weight). However, these differences, which were minor and probably related to low values in the
control group compared to historical controls, are not considered to be adverse.
The statistically significant differences observed in several haematological and clinical chemistry
parameters in the treated groups as compared to control groups showed an unusual dose–response
relationship, where significant changes often were seen only in the low- and mid-dose group.
Differences observed in the high-dose group were minor or not statistically significant compared to the
control group. No macroscopic or histopathological findings were seen in the treated groups.
Statistically significant changes in urinalysis parameters and in some relative organ weights, which
were of low magnitude and occurred only in one gender, are not considered by the Panel to be
treatment-related.
The NDA Panel notes that the treatment of animals by gavage already prior to weaning in the
90-day study in rats, applying a dose range of up to 5,000 mg/kg bw per day of the NF, may induce
variability in some outcomes. The Panel could not interpret the biological relevance and adversity of
the significant differences in the observed haematological and clinical chemistry parameters, which did
not show a dose–response relationship. For this reason and although other parameters did not show
toxicologically relevant differences, the Panel could not establish a no observed adverse effect level
(NOAEL) from this 90-day oral toxicity study with the NF.
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3.10.3. Human data
No human intervention studies with the NF have been provided by the applicant.
The applicant referred to four human studies which have been performed with 2’-FL (alone) obtained
via chemical synthesis. In these randomised, double-blind, controlled intervention studies 2’-FL was
administered either alone or in combination with lacto-N-neotetraose or other oligosaccharides either to
infants or adults (Marriage et al., 2015; Elison et al., 2016; Kajzer et al., 2016; Puccio et al., 2017). In
particular, the study by Elison et al. (2016), which was previously assessed by the Panel (EFSA NDA
Panel, 2015), reported a statistically significant increase in gastrointestinal symptoms (nausea, rumbling,
bloating, passing gas, diarrhoea, loose stools and urgency) in adults consuming 20 g/day of 2’-FL for
2 weeks as compared with the placebo group.
3.11. Allergenicity
The protein content in the NF is below 0.01% (w/w) (limit of reporting (LOR) = 17 mg/kg) as
indicated in the specifications (Table 2). The applicant provided evidence for the absence of the
production microorganisms and residual DNA in the NF.
In addition, the applicant has assessed the allergenic potential of introduced proteins as a result of
the genetic modification of the E. coli K-12 host (which itself is recognised as non-allergenic) using the
search algorithms provided by the Allergen Online tool (version 17) of the University of Nebraska
(FARRP, 2017). No sequence alerts for potential allergenicity were identified.
The Panel considers that the likelihood of adverse allergenic reactions to the NF is very low.
4. Discussion
The NF is a mixture mainly composed of two oligosaccharides, 2’-FL and DFL, which are obtained
by fermentation with a genetically modified strain of E. coli K12. The information provided on the
manufacturing process, composition and specifications of the NF does not raise safety concerns.
The applicant intends to add the NF in a variety of foods, including IF and FOF, foods for infants
and young children, foods for special medical purposes and food supplements. The target population is
the general population except for food supplements, for which the target population is individuals
above 1 year of age.
Considering that 2’-FL and DFL are naturally occurring oligosaccharides present in human milk, the
history of human exposure to 2’-FL and DFL concerns breast-fed infants. The Panel notes that 2’-FL,
which is the major component of the NF, has already been assessed and authorised as a NF to be
added to IF, FOF, to a variety of foods as well as to food supplements.
The Panel considers that there are no concerns regarding genotoxicity of the NF.
The Panels considers that a NOAEL could not be established from the 90-day oral toxicity study
with the NF. However, the intake of 2’-FL and DFL in breastfed infants on a per kg bw basis is
expected to be safe also for other population groups.
The Panel notes that the anticipated daily intake of the NF from the consumption of IF (only), in
infants up to 16 weeks of age, does not exceed the high intake level of 2’-FL and DFL in breastfed infants
per kg bw. The anticipated daily intake of the NF for the proposed uses at their respective maximum use
levels is unlikely to exceed the high intake level of 2’-FL and DFL in breastfed infants per kg bw. Thus, the
Panel considers that the intake of the NF for the proposed uses at their respective maximum use levels
can be considered safe.
The maximum daily intake of the NF as food supplements (i.e. 4 g/day) for individuals above 1 year
of age does not exceed the high intake level of 2’-FL and DFL in breastfed infants per kg bw. Food
supplements are not intended to be used if other foods with added NF or 2’-FL (as well as breast milk
for young children) are consumed the same day.
For foods for special medical purposes, as the applicant did not propose maximum use levels, the
Panel considers that the maximum use levels of the NF should be in accordance with the particular
nutritional requirements of the population segment for which the products are intended but in any
case not higher than the maximum levels specified for the proposed food uses or the maximum daily
intake proposed for food supplements.
5. Conclusions
The Panel concludes that the NF, a mixture of 2’-FL and DFL, is safe under the proposed conditions of
use. The target population is the general population, except for food supplements for which the target
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population is individuals above 1 year of age. Food supplements are not intended to be used if other
foods with added NF or 2’-FL (as well as breast milk for young children) are consumed the same day.
The Panel could not have reached the conclusions on the safety of the NF under the proposed
conditions of use without the following data claimed as proprietary by the applicant:
• annexes to the dossier which relate to the identity, the production process, production
microorganism, composition and specifications of the NF (see annexes indicated in Section 2.1)
• bacterial reverse mutation test (unpublished study report, 2017a), in vitro micronucleus test
(unpublished study report, 2017b), and 90-day oral toxicity study with the NF (unpublished
study report, 2018) including the summary table of the statistically significant observations in
the 90-day study (Appendix B.3 to the dossier). The results of these studies have been
published by Phipps et al. (2018).
Steps taken by EFSA
1) Letter from the European Commission to the European Food Safety Authority with the
request for a scientific opinion on the safety of 2’-fucosyllactose/difucosyllactose mixture.
Ref. Ares(2018)3455328, dated 29/06/2018.
2) On 29/06/2018, a valid application on 2’-fucosyllactose/difucosyllactose mixture, which was
submitted by Glycom A/S, was made available to EFSA by the European Commission through the
Commission e-submission portal (NF 2018/0401) and the scientific evaluation procedure started.
3) On 17/10/2018 and 10/12/2018, EFSA requested the applicant to provide additional
information to accompany the application and the scientific evaluation was suspended.
4) On 29/10/2018 and on 12/03/2019, additional information was provided by the applicant
through the Commission e-submission portal and the scientific evaluation was restarted.
5) During its meeting on 15/05/2019, the NDA Panel, having evaluated the data, adopted a
scientific opinion on the safety of 2’-fucosyllactose/difucosyllactose mixture as a NF pursuant
to Regulation (EU) 2015/2283.
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Appendix A – Summary results of the 90-day repeated dose toxicity study with the NF
Summary results of parameters with statistically significant differences in the 90-day repeated dose toxicity study with the NF (Phipps et al., 2018;













Body weight (g) 9 F 31.2  3.26 32.2  2.02 32.6  1.09 33.5  2.52* 30.8  2.70
Ulna length (mm) 64 M 39.5  0.83 38.3  0.94** 38.6  0.44 39.5  1.04 39.1  1.20
64 F 36.7  0.90 35.7  0.46* 35.6  0.50* 36.3  1.13* 36.4  1.21
Arena observations
Activity count 90 M 17.5  5.0 12.6  5.8 13.2  6.6 17.4  5.6 12.3  6.0^




90 M 43.7  1.91 44.4  1.17 45.3  0.82 45.4  2.23* 45.4  2.59^
Haematology
Haematocrit (L/L) 90 M 0.39  0.01 0.45  0.02** 0.45  0.01** 0.43  0.04** 0.39  0.01
F 0.38  0.02 0.44  0.02** 0.44  0.02** 0.39  0.04 0.38  0.01
Haemoglobin (g/dL) 90 M 14.8  0.35 15.4  0.54* 15.2  0.37* 15.3  0.78* 14.8  0.35
Erythrocytes (9 1012/L) 90 M 7.46  0.33 8.32  0.31** 8.04  0.46** 8.04  0.67** 7.36  0.20
F 7.06  0.34 7.80  0.33** 7.83  0.36** 7.08  0.71 6.95  0.27
MCH (pg) 90 M 19.8  0.62 18.5  0.55* 19.0  0.93* 19.1  1.21* 20.1  0.48
F 20.8  0.68 19.2  0.78** 19.0  0.70** 20.3  1.34 21.3  0.62
MCHC (g/dL) 90 M 37.6  0.57 33.9  0.63** 33.6  0.51** 35.9  2.50** 37.9  0.4
F 38.6  0.85 33.7  0.86** 33.6  0.95** 36.8  2.85 39.3  0.70
MCV 90 M 52.7  1.46 54.5  1.03* 56.5  2.30** 53.3  1.72 52.9  0.9
F 53.9  1.22 56.9  1.38** 56.6  1.41** 55.2  0.90 54.1  1.1
Red cell distribution width (%) 90 M 12.4  0.59 11.7  0.32* 11.6  0.50* 12.3  0.83 12.7  0.40
Leucocytes (9 109/L) 90 F 10.29  3.86 6.92  0.93* 6.34  1.37** 10.82  5.44 10.64  2.08
Lymphocytes (9 109/L) 90 F 8.80  3.65 5.75  0.87** 5.15  1.14** 7.67  1.23 8.80  2.03
Eosinophils (9 109/L) 90 M 0.16  0.06 0.11  0.04 0.09  0.02* 0.18  0.11 0.17  0.06
F 0.14  0.04 0.08  0.03* 0.09  0.04* 0.09  0.03* 0.11  0.04
Basophils (9 109/L) 90 M 0.04  0.01 0.08  0.03** 0.08  0.03** 0.07  0.04** 0.06  0.03^
F 0.03  0.02 0.04  0.02** 0.05  0.02** 0.04  0.02** 0.03  0.01
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Monocytes (9 109/L) 90 F 0.22  0.05 0.15  0.03** 0.12  0.04** 0.17  0.08** 0.24  0.08
LUC (9 109/L) 90 M 0.03  0.01 0.06  0.01* 0.06  0.02** 0.06  0.03** 0.05  0.02
Platelet count (9 109/L) 90 F 976  105.2 907  69.7 813  116.6* 881  137.9* 872  113.6^




M 24.0  40.8 n.a. n.a. 23.2  3.26 22.6  3.33
Clinical chemistry parameters
AST (U/L) 90 M 74  7.3 85  11.8* 84  7.6* 75  4.8 78  10
F 70  11.6 86  13.2* 82  13.7 70  11.8 69  7.6
Albumin (g/L) 90 M 34  1.1 33  1.2 32  1.7** 35  1.8 35  1.2
90 F 40  1.8 37  2.7* 37  1.5* 39  3.8* 38  1.7
Urea (mmol/L) 90 F 5.69  0.58 6.77  0.76* 6.86  1.16* 5.80  1.09 5.94  0.48
Creatinine (lmol/L) 90 M 27  2.5 25  3.1 25  3.1 23  2.1** 25  2.5
Sodium (mmol/L) 90 M 144  1.3 142 1.2 143  1.2 143  1.3 142  1.0^^
F 142  0.5 142  1.6 141  1.4 141  1.2** 141  1.0^
Chloride (mmol/L) 90 M 100  0.8 99  1.3 100  1.0 99  1.2* 98  1.5^^
Calcium (mmol/L) 90 M 2.39  0.06 2.42  0.07 2.40  0.06 2.45  0.06 2.44  0.07^
F 2.43  0.08 2.51  0.10 2.43  0.05 2.54  0.08** 2.41  0.07
Inorganic phosphorus (mmol/L) 90 F 1.77  0.23 1.83  0.31 1.80  0.21 2.03  0.24** 1.77  0.24
Urinalysis
pH 90 F 6.7  0.4 6.8  0.3 7.1  0.5 7.4  0.9** 6.8  0.4
Total creatinine (lmol) 90 F 45.35  6.69 42.45  5.63 41.25  8.27 36.08  9.78* 42.45  8.19
Organ weight –
Kidneys relative 90 M 3.332 3.674** 3.387 3.393 3.153
Seminal vesicles relative 90 M 1.745 1.991* 1.893 1.660 1.673
Thymus relative 90 M 0.321 0.400* 0.387* 0.399* 0.331
NF: novel food; bw: body weight; AST: aspartate aminotransferase; LUC: large unstained cells; MCH: mean cell haemoglobin; MCV: mean cell volume; MCHC: mean cell haemoglobin concentration;
RDW: red cell distribution width.
*: Significantly different from control (p < 0.05) (Vehicle control vs 2’-FL/DFL mixture-treated groups).
**: Significantly different from control (p < 0.01) (control vs 2’-FL/DFL mixture-treated groups).
^: Significantly different from control (p < 0.05) (control vs reference control).
^^: Significantly different from control (p < 0.01) (control vs reference control).
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